Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The main objectives of the project are:
- To classify patients suffering from plaque psoriasis responding on a given treatment
(efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis
Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)
- To characterize patients suffering from plaque psoriasis responding to or not responding
to subcutaneous administrated efalizumab.